Generation of IgG with Galactosylated Glycan Profiles using TransGLYCIT®
Performance Activity
Rapid generation of galactosylated IgG with or without core fucose for structural and functional characterization.

Terminal galactosylation of the IgG Fc glycans result in monogalactosylated (G1) or digalacosylated (G2) glycoforms, with additional fucosylated glycoform variants (G1F and G2F). By generating defined G1 and G2 glycan profiles, the differential impact of galactosylation on the structural and functional properties of the antibody can be analyzed and compared with other defined glycoforms, including both fucosylated and afucosylated glycan profiles.
Galactosylated glycan profiles with and without core fucose were obtained by transglycosylation of trastuzumab using the TransGLYCIT Remodeling and TransGLYCIT Remodeling Afucosylated kits with G1 or G2 glycoforms. Analysis at subunit level using LC-MS (Fig. 1, 2) show mass spectra of the native glycan profile of trastuzumab and the mass shifts after transglycosylation to generate G1F and G2F glycoforms, or afucosylated G1 or G2 glycoforms.
Simple generation of galactosylated IgG with or without core fucose


Related Products
TransGLYCIT® Remodeling Afucosylated
Glycan remodeling of human IgG with the G0, G1, G2, G2S2 or Man5 glycoform, with core afucosylation.

Resources
TransGLYCIT®
Download Product Folder

TransGLYCIT® to Evaluate Fc Effector Function of Therapeutic Antibodies
Download Scientific Poster





